Skip to main content

Table 2 Most common adverse events* (≥4% of subjects) by severity and relationship to study drug (N = 100)

From: A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

Adverse event,% of subjects Total Mild Moderate Severe Related to study drug
Gastrointestinal disorders 5 2 3 0 0
Infections 36 20 14 2|| 1
 Bronchitis 7 0 7 0 0
 Rhinitis 19 16 3 0 1
 Upper respiratory tract infection 9 6 3 0 0
Respiratory, thoracic, and mediastinal disorders§ 4 3 1 0 0
Dermatitis 4 4 0 0 1
  1. *Adverse events were defined as treatment-emergent events, occurring after study drug initiation and within 100 days after the last dose of study drug.
  2. Subjects could have experienced more than 1 adverse event.
  3. Includes anal stenosis, enteritis, and teething.
  4. §Includes bronchopulmonary dysplasia, rhinorrhea, and tonsillar hypertrophy.
  5. ||One case each of pneumonia and tonsillitis.
  6. Possibly related to study drug.